COVID-19: Phase III studies
17 July 2020
Klinfarm Development (CFD) has successfully launched two Phase III multicenter studies to study the safety and efficacy of two drugs aimed at combating the new COVID-19 infection.
Both drugs are representatives of antiviral agents that exhibit antiviral activity against a number of single-stranded RNA-containing viruses.
The company expresses the hope that participation in these studies will allow an impartial assessment of the clinical effect of drugs in a pandemic and bring the timing of promising developments to the Russian market as close as possible.